Barclays
ANAB icon

Barclays’s AnaptysBio ANAB Stock Holding History

Barclays’s Portfolio ANAB Stock Details ANAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-30,000
Closed -$676K – 4842
2024
Q1 		$676K Buy
+30,000
New +$710K ﹤0.01% 3401
2021
Q2 		– Sell
-3,500
Closed -$75K – 4860
2021
Q1 		$75K Buy
+3,500
New +$88.3K ﹤0.01% 4102
2018
Q4 		– Sell
-97,300
Closed -$9.71M – 6903
2018
Q3 		$9.71M Buy
+97,300
New +$8.07M 0.01% 1281

Other funds holding ANAB

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Barclays's ANAB Position: Q2 2026 in Review

Barclays reduced its AnaptysBio (ANAB) stake by 31% in Q2 2026, selling an estimated $141K and leaving 5,107 shares worth $345K. The position accounts for ﹤0.01% of the portfolio, ranked #3414.

Barclays first reported a position in ANAB in Q1 2017 and has held it in 38 quarters since. The position peaked at $12.4M in Q3 2018. 213 funds tracked by Wall St. Rank hold ANAB as of Q2 2026.

  • Barclays held 5,107 shares of AnaptysBio worth $345K as of Q2 2026.
  • Barclays sold 2,333 AnaptysBio shares in Q2 2026, an estimated $141K.
  • AnaptysBio made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #3414 holding.
  • Barclays first reported a position in AnaptysBio in Q1 2017 and has held it in 38 quarters since.
  • Barclays's AnaptysBio position peaked at $12.4M in Q3 2018.
  • 213 funds tracked by Wall St. Rank held AnaptysBio as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.